GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of genuine question about dual agonist that I am slightly embarrassed to ask — 54 comments in the full submission. View in context.
1.3k
c/survodutide·submitted 1 year ago by u/renzo_asante

genuine question about dual agonist that I am slightly embarrassed to ask

Cautionbranch of 7 comments

Slightly embarrassed to be asking this, but: genuine question about dual agonist that I am slightly embarrassed to ask. Imaging-derived liver fat fraction is a surrogate. It correlates with histology imperfectly, and a trial reporting one is not reporting the other. Nothing containing this compound is approved…

Read the full submission and all 54 comments →

This branch

7 comments, started 1 year ago
u/farid_kuipers58 points·1 year ago

read the histology endpoint definitions before quoting a response rate

replysharereportpermalink
u/trialwatch_theoMOD35 points·1 year ago·edited

Removed the escalation schedule. Unapproved compound, no protocols for other members, no exceptions.

replysharereportpermalink
u/renzo_asanteOP19 points·1 year ago

Are you reading the publication or a summary?

replysharereportpermalink
u/renal_outcomes_rnephro-curious0 points·1 year ago

Are you reading the publication or a summary?

renzo_asante is right that biopsy and imaging endpoints are not interchangeable.

replysharereportpermalink
u/britt_okwuosa0 points·1 year ago

Are you reading the publication or a summary?

This is the framing the board needs. It is a hepatic programme first.

replysharereportpermalink
u/customs_seizure_sid16 points·1 year ago

this board is small because the compound is early

replysharereportpermalink
u/deleted_my_history14 points·1 year ago

This. Biopsy-confirmed and imaging-suggested are different evidentiary categories and get run together constantly.

replysharereportpermalink

← back to the whole thread

About c/survodutide

Survodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.

12kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Janoshik Analytical

Independent HPLC and mass spec. The number you get is the number they found.

janoshik.comSponsored

GL Biochem (Shanghai)

Custom peptides and amino acids direct from the manufacturer since 1998. ISO 9001 / cGMP. Batch COA every order.

glbiochem.net
More in c/survodutide
c/survodutide rules
  1. Glucagon co-agonism has a distinct safety story. Do not generalise from tirzepatide.
  2. MASH claims need the trial and the biopsy endpoint.
  3. Not approved. Descriptive posts only.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/liver_enzyme_lizu/trialwatch_theo
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →